Aprogen Medicines Inc. (KRX:007460)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2012
Hard Facing				13.41B	-	29.26B	32.30B	34.42B
Hard Facing Growth				-	-	-9.42%	-6.15%	16.73%
Steel				19.42B	-	34.62B	10.28B	7.51B
Steel Growth				-	-	236.84%	36.84%	-
Insulation (Including NUKON)				2.74B	-	7.17B	6.90B	7.88B
Insulation (Including NUKON) Growth				-	-	3.98%	-12.41%	9.19%
Medicine				32.47B	-	50.80B	25.67B	-
Medicine Growth				-	-	97.84%	-	-
Biopharmaceuticals				9.39B	25.87B	-	-	-
Biopharmaceuticals Growth				-63.69%	-	-	-	-
Other Sales				769.50M	425.33M	2.77B	1.89B	1.24B
Other Sales Growth				80.92%	-84.65%	46.34%	52.75%	-66.27%
Game Business Division				148.30M	-	2.52B	1.20B	-
Game Business Division Growth				-	-	110.23%	-	-
Total				78.35B	26.30B	127.14B	78.25B	51.05B
Total Growth				197.95%	-79.32%	62.48%	53.29%	26.43%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2012
South Korea				68.71B	479.85M	112.40B	-	-
South Korea Growth				14220.02%	-99.57%	-	-	-
Export				9.63B	25.82B	12.02B	-	-
Export Growth				-62.68%	114.78%	-	-	-
Other Areas				-	-	2.72B	-	-
Total				78.35B	26.30B	127.14B	-	-
Total Growth				197.95%	-79.32%	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 23, 2026

Data Sources Report a data error